Definitive Contract HHSO100201700021C

<p>This is a $4,733,100.62 cost-no-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Achaogen, Inc. for the development of &quot;NOVEL LPXC INHIBITORS FOR THE TREATMENT OF CATEGORY A, B, AND C BACTERIAL INFECTIONS&quot;. The contract does not have a set-aside designation. The work is being performed in South San Francisco, California and the contract has an ultimate completion date of June 14, 2022.</p>

<p>The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a Firm Fixed Price Definitive Contract to 98Point6 Inc., a for-profit organization, for comprehensive infectious disease interdiction services. The contract, valued at $257,670.00, does not have a set-aside designation and was awarded on August 6, 2019, with a completion date of February 5, 2021. The place of performance is Seattle, Washington.</p>

The Office of the Assistant Secretary for Preparedness and Response awarded a definitive contract to Basilea Pharmaceutica International Ltd for development of new antibiotics to treat drug-resistant gram-negative bacteria, including public health pathogens, with a ceiling value of $186.5 million on September 15, 2023. The contract is structured as cost-sharing with no set-aside. The award exercises Option 1 (CLIN 0002) and updates the period of performance for the base effort (CLIN 0001)...

This is a $135,127,180.73 definitive, cost-sharing contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Basilea Pharmaceutica International Ltd, doing business as Basilea Pharmaceutica International SA, for the advanced development of the antibiotic ceftobiprole. The contract supports Basilea's work on a new class of antibiotics targeting the lipopolysaccharide transport system in gram-negative bacteria and inhibitors of the...

The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR), awarded a $481.7 million cost-plus-fixed-fee definitive contract to Shionogi Inc. on April 6, 2026, for late-stage development, FDA marketing authorization, procurement, and stockpiling of antibiotics to treat drug-resistant secondary bacterial infections and infections caused by biothreat pathogens. The contract, which extends through March 10, 2036, supports ASPR's...

This is a federal contract award made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Atox Bio LTD, a for-profit organization. The contract, which is a definitive, cost-plus-fixed-fee contract, was originally awarded on September 30, 2014 with a ceiling value of $36,143,630.72. The purpose of the most recent modification is to deobligate $1,484,637.28 in canceling funds, with no other changes to the contract. The contract does not have a...

This is a federal contract award from the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Sab Sciences Inc. The contract has a ceiling value of $2,400,000.00 and is a Cost Plus Fixed Fee Definitive Contract with an ultimate completion date of March 6, 2021. The contract does not have a set-aside designation. The prime contractor is Sab Sciences Inc., and there is no information provided about any major subcontractors. The contract award indicates that Sab...

<p>This is a $732,812.94 firm fixed price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Amplitude Therapeutics, Inc. on August 20, 2024. The contract is for the delivery of an AMPLITUDE THERAPEUTICS-A SPLIT-FORMULATED TRANS-AMPLIFYING RNA ENCODED ANTI-NEURAMINIDASE MONOCLONAL ANTIBODY and has an ultimate completion date of September 30, 2025. The contract does not utilize any set-aside designations.</p>

This is a $4,469,522.01 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Agile Sciences, Inc., a small disadvantaged business. The contract is for &quot;Targeting Therapeutics Development to Relieve Bottlenecks: Optimizing Lead Therapeutic Compounds Against Infectious Pathogens&quot; and has an ultimate completion date of October 15, 2018. The contract was awarded on June 30, 2015 and was not set aside.

This is a firm fixed price delivery order contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Sanofi Pasteur Inc., a foreign-owned, for-profit manufacturer of goods. The contract has a potential value of $339,189.20 and is under a larger Indefinite Delivery Vehicle (IDV) contract named &quot;Pandemic Influenza Preparedness and Response 2016-2021&quot; with a potential value up to $5.87 billion. This contract...